|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2. Primary Outcomes Comparing STS With and Without Fungation** | | | | | | | | |
| **Study** | **Metastasis on presentation** fungating STS vs control | | **Treatment with Amputation** fungating STS vs control | | **Local Recurrence** fungating STS vs control | | **5-Year Overall Survival** fungating STS vs control | |
| *Potter, 2009* | 33% vs. 9% | p = 0.003 | 35% vs 12% | p = 0.01 | 13% vs 14% | not reported | 20% vs 63% | p < 0.0001 |
| *Parry, 2017* | 31% vs 15% | p = 0.055 | 23% vs. 7.8% | p < 0.01 | 20% vs 16.5% | p < 0.006 | 18% vs 56.8% | p = 0.0001 |
| *Okajima, 2021* | 20.0% vs. 11.3% | p = 0.011 | 13% vs 12% | p = 0.74 | --- | --- | 26.0% vs 71.3% | p < 0.0001 |
| STS = Soft Tissue Sarcoma \*Significance level of ⍺ < 0.05 | | | | | | | | |